Deep Dives into Peptide Science
Research breakdowns, protocol design, and the latest findings from the world of peptide science. Written for researchers who care about the evidence.
Epitalon Is Sold on Telomere Science. The New Review Found Four Human Studies.
Epitalon is marketed as a telomere-lengthening longevity peptide. A new Johns Hopkins-led review counted every human study ever published: there are four. Here is what they showed, and why FDA's own scientists opposed compounding it.
GLP-1 Weight-Loss Drugs Lower Blood Pressure. The New Meta-Analysis Shows Why That Matters.
A 37-trial review links greater average weight loss with greater systolic blood-pressure reduction. Here is what the 50,171-participant analysis supports—and what it cannot prove.
Semaglutide Changed Decision-Making in a Depression Trial. That Does Not Mean It Treats Depression.
A 72-person randomized-trial analysis found changes in modeled reward-based choices after oral semaglutide. The result is a research signal—not evidence the drug relieves depression.
A Weekly Oral Peptide Obesity Pill? Ascletis Has Monkey Data, Not Human Proof
Ascletis reports a seven-day half-life for oral amylin peptide ASC36o in monkeys and says its Phase 1 study is underway. Here is what the data do—and do not—show.
Oral Peptide Icotrokinra Shows a Psoriatic Arthritis Signal. The Trial Wasn’t Designed to Prove It.
A post hoc analysis found better patient-reported joint pain and disease activity with icotrokinra—but dedicated psoriatic arthritis trials are still needed.
GLP-1 Drugs and PCOS Fertility: A New Review Finds a Natural-Pregnancy Signal, Not an IVF Answer
A new review of three randomized trials finds a natural-pregnancy signal for GLP-1-based treatment in PCOS—but no clear benefit for overall or IVF pregnancy. Here is what the limited evidence means, and why medication timing matters.
An Oral Peptide for Ulcerative Colitis: Icotrokinra’s Phase 2 Signal, Without the Shortcut Claims
A randomized phase 2b trial found higher week-12 response rates with oral icotrokinra than placebo. Here is what the ulcerative-colitis results establish—and what they do not.
Pumpkin-Seed Peptide Supplement: What a Small Human Trial Actually Found
A randomized trial tested a pumpkin-seed peptide preparation. The overall results were null; a 13-person subgroup raised a question, not a conclusion.
Apelin: The Peptide Your Body Already Makes Just Showed Up in Five Major Studies
Between September and October 2026, apelin appeared in Diabetologia, JCI Insight, and Kidney360, attached to kidney disease, pulmonary hypertension, heart failure, and Parkinson's. Here is what the primary papers actually found, and what keeps failing.
A Mitochondrial Peptide Just Rejuvenated Aged Human Eggs in the Lab. Here's What the Science Actually Shows.
Elamipretide restored egg quality in aged mice and improved maturation of aged human oocytes in a new Aging Cell study. The drug is already FDA-approved for a rare disease. Does that make it a fertility breakthrough — or another promising mouse story? We read the paper.
An Oral GLP-1 Pill Just Passed Its First Cardiovascular Test. Read the Death Numbers Carefully.
ACHIEVE-4 put orforglipron head-to-head against basal insulin in 2,749 high-risk adults. It cleared the safety bar, lost on tolerability, and produced a mortality signal its own sponsor warns not to overread.